Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial

• Ngā kaituhi matua: José Luis Hernández (Author), Francisco S Lozano (Author), Vincent Riambau (Author), Manuel Almendro-Delia (Author), Juan Cosín-Sales (Author), Sergi Bellmunt-Montoya (Author), Javier Garcia-Alegria (Author), Xavier Garcia-Moll (Author), Juan José Gomez-Doblas (Author), José R Gonzalez-Juanatey (Author), Carmen Suarez Fernández (Author)
• Hōputu: Pukapuka
• I whakaputaina: BioExcel Publishing Ltd, 2020-07-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Patients with peripheral artery disease (PAD) are at a high risk not only for the classical cardiovascular (CV) outcomes (major adverse cardiovascular events; MACE) but also for vascular limb events (major adverse limb events; MALE). Therefore, a comprehensive approach for these patients should incl...